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Context: Genetic factors are major determinants of thyroid function. Over the last two decades, 
multiple genetic variants have been associated with variations in normal range thyroid function 
tests. Most recently, a large-scale genome-wide association study (GWAS) doubled the number of 
known variants associated with normal range thyrotropin (TSH) and free thyroxine (FT4) levels.
Evidence Acquisition: This review summarizes the results of genetic association studies on 
normal range thyroid function and explores how these genetic variants can be used in future 
studies to improve our understanding of thyroid hormone regulation and disease.
Evidence Synthesis: Serum TSH and FT4 levels are determined by multiple genetic variants 
on virtually all levels of the hypothalamus-pituitary-thyroid (HPT) axis. Functional follow-
up studies on top of GWAS hits has the potential to discover new key players in thyroid 
hormone regulation, as exemplified by the identification of the thyroid hormone transporter 
SLC17A4 and the metabolizing enzyme AADAT. Translational studies may use these genetic 
variants to investigate causal associations between thyroid function and various outcomes in 
Mendelian Randomization (MR) studies, to identify individuals with an increased risk of thyroid 
dysfunction, and to predict the individual HPT axis setpoint.
Conclusions: Recent genetic studies have greatly improved our understanding of the genetic 
basis of thyroid function, and have revealed novel pathways involved in its regulation. In 
addition, these findings have paved the way for various lines of research that can improve our 
understanding of thyroid hormone regulation and thyroid diseases, as well as the potential use 
of these markers in future clinical practice. (J Clin Endocrinol Metab 105: 1–15, 2020)
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Thyroid diseases are common and have a negative impact on multiple health outcomes (1). Large observational and population-based studies showed that even variation in thyroid function within the ref-
erence range is associated with adverse clinical out-
comes, such as atherosclerotic cardiovascular disease 
(2), stroke (3), atrial fibrillation (4), type 2 diabetes 
(5), metabolic syndrome (6), fracture risk (7), dementia 
(8), depression (9), increased risk of thyroid cancer in 
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patients with thyroid nodules (10–12), and mortality 
(13). Therefore, it is essential to understand the mech-
anisms underlying these variations in thyroid function. 
In healthy persons, serum TSH and thyroid hormone 
(TH) levels show substantial interindividual variation, 
while the intraindividual variation lies within a much 
narrower range (14). The observed interindividual vari-
ation can be partially attributed to differences in indi-
vidual characteristics (eg, age and BMI) and exposure to 
environmental factors (eg, iodine intake) (15). However, 
studies in mono- and dizygotic twins demonstrated that 
genetic factors are major determinants of thyroid func-
tion, responsible for 45–65% of the interindividual vari-
ation in TSH and TH levels (16). It has been suggested 
that besides rare variants with large effects (mutations), 
the overall effect of the genetic factors on an individual’s 
TSH and TH levels is determined by multiple common 
variants (polymorphisms) with small effect sizes (17, 18). 
Over the last two decades, several genetic variants have 
been associated with thyroid function in candidate gene 
studies, while more recently, many more variants were 
identified in genome-wide association studies (GWAS) 
(17, 18). The largest GWAS on thyroid function to date 
has been recently performed within the ThyroidOmics 
Consortium in 72 000 individuals and greatly increased 
the number of associated genetic variants (19). In the 
current review, we will discuss the knowns and un-
knowns of the genetic factors involved in the regula-
tion of thyroid function, with a special emphasis on 
the most recently identified variants. Moreover, we will 
discuss several approaches in which these novel data 
can be used to improve our understanding of thyroid 
physiology and disease, as well as the potential use of 
these markers in future clinical practice.
Genetic Determinants of Thyroid 
Function
Early work on genetic determinants of thyroid function 
often involved candidate gene studies that analyzed a 
limited number of genetic variants located within spe-
cific genes selected based on their known function. Later 
on, GWAS allowed researchers  to investigate the asso-
ciation of approximately 1  000  000 independent gen-
etic variants across the entire genome with the trait of 
interest, using a hypothesis-free approach (20). To avoid 
false-positive results due to multiple testing, an ad-
justed P-value threshold (P  <  5  ×  10-8) is used to de-
clare statistical significance in GWAS (21). Large sample 
sizes are therefore required to ensure sufficient power. 
The first GWAS on TSH levels, performed in 2008 by 
Arnaud-Lopez et  al in 4300 Sardinians, identified one 
genome-wide significant locus (ie, Phosphodiesterase 
8B  [PDE8B]) (22). This list was further extended by 
several larger GWAS performed by Gudmundsson et al 
(23), Porcu et al (24), and others (25–31). As illustrated 
in Figure 1, the increasing number of subjects included in 
every next GWAS led to a steep increase in newly iden-
tified variants. The most recent GWAS performed by the 
ThyroidOmics Consortium (www.thyroidomics.com) 
identified 19 novel loci associated with normal range 
TSH levels and 16 novel loci associated with normal 
range free thyroxine (FT4) levels, leading to a total of 42 
and 21 known and novel associated loci for these two 
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Figure 1. Identified serum TSH and/or FT4 associated loci over time, using different study techniques. Variants found to be significant 
in candidate gene studies were included when associations were replicated in at least one independent population (N > 500) or in case of in vitro 
evidence for functionality. Abbreviations: GWAS, genome-wide association study; N, number of subjects analyzed in the study; WGS, whole-
genome sequencing.
Copyedited by: oup
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/6/dgz225/5818501 by Erasm
us U
niversity R
otterdam
 user on 08 June 2020
doi:10.1210/clinem/dgz225 https://academic.oup.com/jcem  3
traits (Figures 1 and 2) (19), which we briefly discuss in 
this section. As variants associated with hypothyroidism 
and hyperthyroidism are not in the scope of this review, 
we refer to previous comprehensive reviews (17, 32, 33).
Established players
The results of genetic association studies demonstrate 
that TSH and TH levels are determined by variants in 
genes involved in the regulation of thyroid function 
on virtually all levels of the hypothalamus-pituitary-
thyroid (HPT) axis and peripheral thyroid hormone 
regulation (17, 18). Based on their function, these genes 
can be classified into several groups, which often tend 
to predominantly determine either TSH or TH levels, as 
presented in Table 1. We highlight typical examples for 
each of these groups below.
Genes encoding proteins implicated in develop-
ment and function of the HPT axis. Several variants 
associated with TSH and/or TH levels localize within 
genes encoding proteins implicated in the development 
and function of the HPT axis. These include important 
transcription factors as well as growth factors and their 
binding proteins (Table 1).
Transcription factors. The first group includes vari-
ants in genes encoding transcription factors expressed 
in the HPT axis, which are often associated with both 
TSH and TH levels (Table 1). The associated biochem-
ical fingerprint depends on whether these factors pri-
marily contribute to the development and function of 
the thyroid or pituitary. For example, LIM homeobox 
3  (LHX3) encodes a transcription factor involved in 
pituitary development. LHX3 variants have been pre-
dominantly associated with lower FT4 levels, with 
either no effects on TSH levels (16) or lower TSH 
levels  (21), which is indeed the hallmark of a central 
hypothyroidism-like effect. This is supported by the 
observation that inactivating mutations of the LHX3 
gene can lead to central congenital hypothyroidism ac-
companied by growth hormone and gonadotropin defi-
ciency (42).
On the other hand, variants of genes encoding tran-
scription factors primarily involved in thyroid develop-
ment and function tend to be associated with FT4 and 
TSH levels in the opposite direction, as illustrated by 
variants in the GLIS family zinc finger 3 (GLIS3) gene. 
GLIS3 encodes a zinc finger transcription factor, acting 
as both repressor and activator of gene transcription 
Figure 2. Manhattan plots of the GWAS meta-analysis results for TSH and FT4 contrasted with each other. Single nucleotide 
polymorphisms (SNPs) are plotted on the x-axis according to their position on each chromosome with -log10 (p-value) on the y-axis. The upper solid 
horizontal line indicates the threshold for genome-wide significance, ie, 5x10-8. Genomic loci previously known to contain trait-associated variants 
are colored in black, new loci in gray. Adapted from Teumer et al (19). 
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in the thyroid (43). Animal models and in vitro studies 
showed that GLIS3 is essential for proliferation of thy-
roid follicular cells and synthesis of TH, as it is involved 
in transcription of the iodide transporters, sodium iodide 
symporter (NIS/SLC5A5) and pendrin (PDS/SLC26A4) 
(44). Mutations in the GLIS3 gene have been associated 
with primary congenital hypothyroidism, accompanied 
by neonatal diabetes (45). Of note, GLIS3 was the only 
locus associated with both TSH and FT4 levels at the 
genome-wide significant level in the most recent GWAS 
(19), and the same GLIS3-rs10814915 allele was asso-
ciated with higher TSH and lower FT4 levels.
Growth factors and their binding proteins. Variants 
in genes encoding growth factors expressed in the thy-
roid are also predominantly associated with TSH levels 
and, to a lesser extent, with FT4 levels in the opposite 
direction (Table 1). Such biochemical fingerprints were 
indeed noted for variants in VEGFA (encoding vas-
cular endothelial growth factor A) and FGF7 (encoding 
fibroblast growth factor 7). VEGFA promotes angio-
genesis and proper microvasculature development, 
which is essential for iodine and TSH supply to the 
thyrocytes (46,47). In turn, FGF7 plays an important 
role in thyroid development and promotes thyrocyte 
proliferation (48). Of note, FGF7 was also one of the 
significant hits in the goiter GWAS by Teumer et  al 
(49). Interestingly, the same FGF7-rs4338740 allele 
was associated with both increased thyroid volume in 
the study by Teumer et al (49) and lower TSH levels 
in several GWAS (19, 23, 24). These findings are in 
line with the results of observational studies showing 
that higher thyroid volume is associated with lower 
TSH levels in euthyroid adults (50–52) and children 
(53, 54). These results suggest that variants associ-
ated with increased FGF7 activity result in increased 
thyroid cell mass and volume, and it appears that for 
these thyroids lower TSH levels are required to main-
tain normal FT4 levels.
Genes encoding proteins involved in the TSH re-
ceptor signaling cascade. Another important group 
of genetic determinants of thyroid function  includes 
variants in genes encoding the TSH receptor (TSHR) 
and other proteins involved in the cascade, which fol-
lows after TSH is bound to the TSHR. As can be physio-
logically expected, such variants primarily affect TSH 
levels (Table 1), with some also having minor effects on 
TH levels in the opposite direction. This can be illus-
trated by variants in the PDE8B gene. PDE8B encodes 
a phosphodiesterase, which is highly expressed in the 
thyroid and responsible for the inactivation of cyclic 
adenosine monophosphate (cAMP), which is produced 
after TSHR activation. All large GWAS have identified 
that several PDE8B variants are associated with serum 
TSH levels, while their association with FT4 levels is 
much weaker (19,23,24). It is speculated that the identi-
fied genetic variants increase PDE8B activity, leading to 
lower cAMP levels. Consequently, a higher TSH level is 
required to maintain normal FT4 levels.
Genes encoding TH transporters and enzymes in-
volved in TH metabolism. In contrast, variants in genes 
encoding proteins involved in TH transport and metab-
olism result in altered TH levels without any evident 
change in TSH levels (Table 1). This can be illustrated 
by DIO1 encoding type 1 iodothyronine deiodinase. 
Several independent DIO1 variants have been associ-
ated with TH levels but not TSH levels in GWAS and 
candidate gene studies (19, 24, 36, 40, 41). DIO1 plays 
an important role in the peripheral conversion of thy-
roxine (T4) to triiodothyronine (T3) and the degrad-
ation of reverse T3 (rT3). Therefore, variants associated 
with lower DIO1 activity lead to higher T4 levels and 
lower T3 levels, resulting in a net euthyroid status, as re-
flected by the absence of an association with TSH.
The examples above illustrate that the identified ef-
fects of many variants fit nicely with the gene’s role 
in TH regulation. In turn, the biochemical fingerprint 
of variants in genes with a yet unknown role in TH 
regulation can therefore also be used to provide clues 
about the role of the associated gene in the HPT axis 
or peripheral TH regulation. This is illustrated by 
the recent identification of the roles of aminoadipate 
aminotransferase  (AADAT)  and solute carrier family 
17 member 4  (SLC17A4)  in TH regulation, which we 
discuss more extensively below. The exact location of 
the gene in the HPT axis and their associated effects on 
TSH and TH levels is also important when considering 
the use of these variants in Mendelian Randomization 
and prediction studies, as discussed later in this review.
Novel players
The most recent GWAS on thyroid function doubled 
the number of loci associated with TSH and FT4 levels 
(19). This included novel variants within known thyroid-
related genes or related pathways, but also a number of 
variants within genes without an established role in the 
regulation of TSH and FT4 levels (Table 1). Functional 
follow-up studies on two of these genes (AADAT and 
SLC17A4) confirmed their role in TH regulation, as 
discussed below.
AADAT – a novel thyroid hormone metabolizing 
enzyme. GWAS have found that genetic variation in 
the AADAT locus is associated with variation in FT4 
levels (19, 24). AADAT is highly expressed in multiple 
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tissues, including the liver, gastrointestinal tract, and 
kidney (55), but until recently its role in TH regulation 
remained completely unknown. Given the observed 
associations with TH levels and the fact that AADAT 
encodes a mitochondrial aminotransferase with broad 
substrate specificity, Dr Theo Visser postulated that 
AADAT could encode a TH metabolizing enzyme. This 
was indeed confirmed by in vitro studies, in which cell 
lysates of human AADAT transfected cells were in-
cubated with THs. When compared to empty vector 
transfected cells, this led to an increased conversion 
of THs (amongst others, T4 and T3) to their pyruvic 
acid metabolites (19). Further studies showed that the 
identified AADAT gene variant (rs6854291) was also 
associated with lower serum T3 levels and a lower T3/
T4 ratio (19). These results show that AADAT is a TH 
metabolizing enzyme, which is likely to play a critical 
role in the rate of TH metabolism.
SLC17A4 – a novel thyroid hormone transporter. The 
most recent GWAS on FT4 levels identified two inde-
pendent variants within the SLC17A4 gene (rs9356988 
and rs137964359) to be associated with FT4 levels (19). 
The SLC17A4 gene encodes an organic anion trans-
porter that is particularly expressed in the liver, kidney, 
and gastrointestinal tract (56,57). Given its associ-
ation with TH levels, it was postulated that SLC17A4 
could encode a TH transporter. In vitro studies indeed 
confirmed that SLC17A4 is a high-affinity T3 and T4 
transporter, with similar properties as monocarboxylate 
transporter 8 (MCT8), the most specific TH transporter 
identified to date (19).
DIO3OS – a potential regulator of DIO3 expres-
sion. Type 3 deiodinase (DIO3) is responsible for the 
degradation of TH (T4 to rT3 and T3 to T2). In mice, 
DIO3 is critical for the maturation and function of the 
HPT axis, as mice lacking DIO3 activity develop peri-
natal thyrotoxicosis followed by mild central hypothy-
roidism in adulthood (58, 59). Whereas genetic variation 
in DIO3 was found not to be associated with TSH and/
or TH levels in humans in candidate gene studies (36, 
40, 41) or previous GWAS (22–31), two independent 
variants within the DIO3 opposite strand upstream 
RNA  (DIO3OS) gene have been associated with FT4 
levels in the most recent GWAS on thyroid function 
(19). DIO3 and DIO3OS are overlapping genes tran-
scribed in opposite directions (60), and Kester et al dem-
onstrated that DIO3 and DIO3OS are co-expressed in 
various human cell lines (61). Whereas DIO3 is an im-
printed gene, DIO3OS may be involved in maintaining 
monoallelic expression of DIO3 (62, 63), which could 
explain the observed associations with TH levels. Future 
studies should clarify whether these variants indeed af-
fect DIO3 expression.
Novel variants within thyroid-related genes and 
known pathways. Type 2 iodothyronine deiodinase 
(DIO2) is involved in the conversion of T4 to T3 and 
rT3 to T2. The most frequently tested DIO2 variants are 
rs225014 (also known as p.92T > A) and rs12885300 
(also known as ORFa-Gly3Asp). DIO2-rs12885300 is 
located in a short open reading frame within the 5’UTR 
of the DIO2 gene. This part of the gene is thought to 
be responsible for the inhibitory effect of the 5’UTR 
on DIO2 transcription, which is supported by in vitro 
analyses showing that the Asp variant is associated with 
increased gene transcription and DIO2 activity (64). 
In line with this finding, Peeters et al showed that this 
variant is associated with an increased T3/T4 ratio (65). 
However, this could not be replicated by others (66, 
67), while this variant was neither associated with T4 
levels in the most recent GWAS (19), suggesting that this 
variant does not have any substantial effects on circu-
lating T3 and T4 levels, or their ratio.
DIO2-rs225014 is a non-synonymous variant re-
sulting in the Thr92Ala substitution, which has been in-
vestigated in several in vitro studies (36, 68–70). Initial 
studies did not find effects of the Ala variant on T4 to T3 
conversion in transfected human kidney (HEK) cells and 
fibroblast-like cells derived from monkey kidney tissue 
(COS cells) (36, 68). However, Canani et al did show 
decreased DIO2 activity in muscle and thyroid samples 
from patients with type 2 diabetes mellitus who were 
homozygous for the Ala variant (68). More recently, 
Castagna et  al performed a series of experiments on 
DIO2-rs225014 functionality in mice, amongst others, 
demonstrating lower T4 to T3 conversion in DIO2-
92Ala-transfected myoblasts and pituitary cells  com-
pared with DIO2-92Thr-transfected myoblasts and 
pituitary cells in DIO2-null mice (69). Collectively, 
these studies provide strong evidence for the functional 
effects of the DIO2-rs225014 variant in multiple cell 
lines. Despite this, DIO2-rs225014 was not associated 
with serum TSH and/or TH levels in several candidate 
gene studies (36, 67, 71, 72) and previous GWAS (24, 
28, 29). However, the most recent GWAS proved that 
rs225014 and two other DIO2 variants (rs150816132 
and rs978055, but not rs12885300) are indeed associ-
ated with normal-range FT4 levels (19), which clearly 
demonstrates the advantage of well-powered large-scale 
studies in identifying variants associated with thyroid 
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function. Multiple studies investigated the potential clin-
ical implications of the DIO2-rs225014 variant, which 
we will discuss later in this review. Of note, the recent 
GWAS also provided evidence for other thyroid-related 
genes (eg, TSHR, TG, OATP1B1) and identified several 
novel independent variants within the established loci 
(eg, PDE8B, CAPZB, DIO1) (Table 1).
Genes of unknown function in thyroid hormone 
regulation
Finally, a large part of the newly and previously identi-
fied loci (eg, MAF, PRDM11, DIRC3, CA8, PRKX, XKR4, 
and SNX29; see Table 1) do not have any known role in 
TH regulation. These loci form a particularly interesting 
group for further research, possibly elucidating new path-
ways in thyroid physiology as illustrated by the successful 
in vitro studies on AADAT and SLC17A4. Importantly, 
GWAS hits do not necessarily always pinpoint causal 
variants and genes, as the observed association might in 
some cases result from linkage disequilibrium with other 
(rare) variants yielding the causal effect (73). For ex-
ample, the beta-1,4-galactosyltransferase 6  (B4GALT6) 
variant (rs113107469) identified by Taylor et al (34) is 
tagging a much rarer and potentially functional variant 
(rs28933981, minor allele frequency of 0.4%) in the 
gene  encoding transthyretin (TTR), resulting in the 
Thr139Met substitution, which was associated with 
an increased thyroxine-binding affinity (34). Therefore, 
follow-up studies for these loci are a key next step to 
understand the mechanisms underlying the observed 
associations.
Implications for Clinical Practice
As reviewed above, many genetic determinants of thy-
roid function have been identified in the last few years. 
Here we discuss ways in which these data could serve 
future clinical practice. In particular, we will discuss 
how identified genetic variants could be used to: (1) in-
vestigate causal associations between thyroid function 
and adverse outcomes, (2) predict the individual risk of 
thyroid dysfunction and its response to treatment, and 
(3) define the individual HPT axis setpoint.
Mendelian randomization studies
In the last decade, multiple observational studies 
have reported associations between minor variations 
in thyroid function and adverse clinical outcomes (2-9, 
13). This has opened up a discussion whether reference 
ranges for thyroid function tests should be adapted (74, 
75). However, observational studies are prone to biases 
in study design, residual confounding, and reverse caus-
ality (76). In most cases, it is therefore unclear whether 
causal relationships underlie the observed associations. 
One possible and currently popular approach is to per-
form a Mendelian Randomization (MR) study. In MR, 
the effect of an exposure (eg, thyroid function) on an 
outcome (eg, cardiovascular disease) is evaluated using 
genetic variants associated with the exposure as the in-
struments (Figure 3). This concept draws from the fact 
that genetic variants segregate randomly from parents 
to offspring, which can be compared to randomization 
used in clinical trials. As genetic variants can affect an 
outcome (via exposure) but not the other way around, 
an association between the genetically estimated ex-
posure and outcome can confirm the causality of the 
observed association. However, this approach requires 
several assumptions (77, 78). Most importantly, the in-
struments have to be truly associated with the exposure, 
and the effect of the instruments on the outcome has 
to be mediated solely by the exposure. This means that 
weak and pleiotropic instruments should be avoided 
since they can strongly bias the causal estimates (79, 
80). Another important prerequisite is that a conclusive 
MR requires appropriate power, which depends on sev-
eral parameters, including study sample size, magnitude 
Confounders
Genec
variants
Outcome
2.
1.
3.
MR – core assumpons
1. The genec variants used
as instruments must be 
truly associated with the 
exposure.
2. The genec variants
should only be related to 
the outcome of interest 
through the exposure 
under study.
3. The genec variants
should not be associated 
with any confounders of 
the exposure-outcome 
relaonship.
Exposure
Figure 3. Core assumptions for Mendelian Randomization (MR) studies. Arrows indicate the direct effect of one variable on the other, while 
dashed arrows with a cross indicate that there should be no direct effect of one variable on the other.
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of the causal association between the exposure and out-
come, and proportion of variance in the exposure ex-
plained by the genetic instruments used (81).
Several MR studies have attempted to clarify the 
causal relationships between minor variation in thy-
roid function and various outcomes, including cardio-
vascular disease (82, 83), type 2 diabetes (84), bone 
mineral density and fracture risk (85), and kidney func-
tion (86). However, none of them found evidence for 
a causal association between thyroid function and the 
tested outcome. More recently, two MR studies (87, 88) 
provided evidence for causal effects of minor variation 
in thyroid function on atrial fibrillation (AF) risk, as 
they found that genetically-predicted decreased TSH 
levels, as well as increased FT3:FT4 ratios (but not FT4 
levels), were associated with an increased risk of AF 
(87, 88). While negative results of MR studies could 
indicate lack of causal effects of thyroid function on 
tested outcomes, they might also result from insuffi-
cient power to detect existing effects. The identification 
of many novel genetic variants associated with serum 
TSH and FT4 levels in the most recent GWAS by the 
ThyroidOmics Consortium will significantly increase 
the power of future MR studies. However, there are 
more requirements to ensure a high quality of future 
MR studies (89). First of all, a good understanding of 
mechanisms underlying the association between thy-
roid function and genetic variants used as instruments 
in MR studies is essential. For example, several DIO1 
variants have been associated with FT4 levels in GWAS. 
Since DIO1 is responsible for peripheral conversion of 
T4 to T3, the higher T4 levels coincide with lower T3 
levels, leading to a net euthyroid status, as reflected by 
the absence of an association with TSH. Consequently, 
while these variants can be used as instruments for vari-
ation in normal-range FT4 levels, they should not be 
interpreted as being instruments for increased thyroid 
function, despite their relation with higher FT4 levels. 
Therefore, a good understanding of the role of iden-
tified loci in the HPT axis and their resulting associ-
ations with thyroid function tests (Table  1) is a key 
for an appropriate interpretation of MR study results. 
Moreover, it is important to remember that thyroid 
dysfunction is mostly caused by autoimmunity and 
that autoimmune diseases frequently coincide. For this 
reason, it is not always clear whether the causal effect 
of hypothyroidism or hyperthyroidism on an outcome 
observed in a MR study is attributed solely to thyroid 
dysfunction or rather to concomitant autoimmune dis-
orders. Furthermore, even the associations with normal 
range TSH and FT4 levels can reflect either alterations 
in the HPT axis setpoint or mild (early stage) thyroid 
disease. Data from GWAS on (subclinical) hypo/hyper-
thyroidism (19) and thyroid peroxidase antibody posi-
tivity (90) available at the ThyroidOmics Consortium 
website (www.thyroidomics.com; genetic associations 
section) can be used to distinguish between these two 
groups.
Predicting the individual risk of thyroid disease 
and treatment response
It is an intriguing question as to whether data from 
large-scale genetic association studies can eventually 
serve the management of individual patients. In the fol-
lowing sections we discuss the potential role of genetic 
variations in DIO2, as well as the use of genetic risk 
scores (GRS).
Type 2 deiodinase.  Approximately 70% of circulating 
T3 derives from peripheral T4 deiodination catalyzed 
by DIO2 (91). As discussed above, DIO2-rs225014 has 
been shown to affect DIO2 activity in several cell lines 
(68–70). Several small-scale epidemiological studies 
have shown associations between this variant and 
various clinical endpoints, including type 2 diabetes, 
hypertension, osteoarthritis, bipolar disorder, and others 
(17, 18, 92). Additionally, it has been hypothesized that, 
because of impaired T4/T3 conversion, hypothyroid 
patients harboring the Ala variant may experience a 
benefit from LT4/LT3 combination therapy. For these 
reasons, three clinical studies have assessed the poten-
tial role of this variant in determining LT4/LT3 combin-
ation therapy efficacy. The first study was performed by 
Appelhof et al (71) in 2005, who did not find effects of 
the DIO2-rs225014 genotype on baseline well-being or 
appreciation of LT4/LT3 combination therapy in 141 
hypothyroid patients (P > 0.05). In 2009, Panicker et al 
(93) performed a retrospective analysis in 552 hypo-
thyroid patients from the Weston Area T4 /T3 Study 
(WATTS), in which patients on a stable dose of LT4 
therapy were previously randomized to either LT4/LT3 
combination therapy or the original LT4 monotherapy 
dose (94). In this study, patients homozygous for the Ala 
variant had an impaired psychosocial well-being at base-
line as assessed by the General Health Questionnaire 
(GHQ) and showed greater improvement in the GHQ 
score on LT4/LT3 combination therapy when com-
pared with LT4 monotherapy (by 2.3 GHQ points at 
3 months and 1.4 points at 12 months, P = 0.03) (93). 
However, these results were not statistically significant 
when correcting for multiple testing, whereas signifi-
cant heterogeneity in baseline psychosocial well-being 
and improvement on LT4/LT3 combination therapy 
was observed within the groups of patients stratified by 
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the DIO2-rs225014 genotype (93). No association be-
tween the DIO2-rs225014 variant and health-related 
quality of life measured using the RAND36-Item Health 
Survey (95) was either found in 364 patients on LT4 
treatment by Wouters et  al (72). More recently, Carle 
et  al (96) performed a small (N  =  45) prospective 
double-blind randomized clinical trial in which they 
found that hypothyroid patients harboring combined 
MCT10-rs17606253 and DIO2-rs225014 variants 
(P = 0.009), but not DIO2-rs225014 alone (P > 0.05), 
may prefer LT4/LT3 combination treatment. While 
these results need to be interpreted with caution given 
the small sample size of the study (96), they may sug-
gest that a combination of multiple variants, rather 
DIO2-rs225014 alone, may contribute to differences 
in response to LT4/LT3 combination therapy observed 
between patients. In summary, while it has been proven 
that the DIO2-rs225014 variant affects DIO2 function 
as well as circulating serum T4 levels, it is highly unlikely 
that this single variant alone is of substantial predictive 
value in the individual patient. The interindividual dif-
ferences in response to LT4 monotherapy, as well as 
LT4/LT3 combination therapy, are more likely to be ex-
plained by a combination of multiple variants (common 
or rare with large individual effects sizes), which should 
be the scope of future genetic and clinical studies.
Genetic risk scores. The most prominent research 
using GRS comes from the cardiovascular field. For ex-
ample, using a GRS that combined 50 single nucleotide 
polymorphisms (SNPs) associated with coronary artery 
disease (CAD) in GWAS, Khera et al (97) showed that 
participants with a GRS in the highest quintile had a 
91% higher relative risk of incident coronary events 
compared to those with a GRS in the lowest quintile. 
A more robust polygenic score was able to identify 8% 
of population at a greater than threefold increased risk 
of CAD (98). Given the ongoing identification of novel 
genetic variants associated with CAD and the continu-
ously decreasing costs of genotyping arrays, imple-
mentation of such GRS into everyday clinical practice 
starts to be considered as a cost-effective method for 
improving the effectiveness of prevention and treatment 
for CAD (99, 100).
As GWAS on thyroid function have identified many 
variants in the last decade (Figure  1), a number of 
studies have also investigated the use of these variants 
to identify individuals with increased risk of thyroid 
dysfunction. In a follow-up analysis for their GWAS 
on serum TSH and FT4 levels using GRS based on 20 
variants associated with normal range TSH levels, Porcu 
et al (24) showed that the odds of increased TSH levels 
were 6.65 times greater in individuals with a GRS in 
the top quartile compared to individuals in the bottom 
quartile (P  =  3.4x10-20). In another study, Schultheiss 
et al (101) showed that a GRS based on nine variants as-
sociated with thyroid peroxidase antibodies (TPOAbs) 
in a dedicated GWAS (90) can be used to identify indi-
viduals with an increased risk of both overt and sub-
clinical hypothyroidism (interquartile odds ratio of 
1.89 and 1.80, respectively). Furthermore, the most 
recent GWAS on thyroid function also showed that 
a GRS based on variants associated with TSH levels 
within the normal range strongly correlates with the 
risk of both (subclinical) hypothyroidism and hyper-
thyroidism (Figure 4) (19). However, it should be noted 
that while showing impressive effects at the extremes, 
the number of subjects carrying extremely low or high 
GRS was limited, and these markers still have insuffi-
cient discriminatory power to be used in clinical prac-
tice. Nevertheless, these results illustrate in which ways 
they could be used to help identify individuals with an 
increased risk of thyroid dysfunction or personalize the 
treatment of patients with thyroid disease in the future.
Defining the individual HPT axis setpoint
Serum TSH and TH levels in healthy persons 
show substantial interindividual variation, while the 
intraindividual variation is much smaller (14). This 
Figure 4. Associations of genetic risk scores with 
hypothyroidism and hyperthyroidism. The probability of 
hypothyroidism (gray) or hyperthyroidism (black), as defined by an 
increased or decreased TSH, respectively, based on a weighted genetic 
risk score (GRS) built using the 61 SNPs associated with TSH levels in 
the most recent GWAS by Teumer et al (19) is shown with respect to 
the percent of total risk alleles (x-axis). The gray histogram shows the 
distribution of the GRS in the study sample. Adapted from Teumer 
et al (19).
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suggests that every person has a unique individual TSH 
and TH setpoint. Therefore, normalization of TSH and 
TH levels in thyroid disease patients after the initi-
ation of treatment to levels within the reference ranges 
cannot guarantee the euthyroid status of that specific 
individual, as the achieved levels can still deviate from 
the individual setpoint. In addition, even TSH and 
TH levels within the reference range have been asso-
ciated with an increased risk of cardiovascular events, 
including atherosclerotic cardiovascular disease and 
stroke (2, 3). Unfortunately, we seldom have TSH and 
TH levels before the onset of the thyroid disease, which 
could be used as a proxy of the individual setpoint. 
Mathematical models based on repeated measure-
ments of TSH and TH levels of an individual on LT4 
therapy have been proposed to estimate the individual 
HPT axis setpoint (102, 103), but this approach still 
requires clinical validation. While we currently cannot 
predict an individual’s HPT axis setpoint, we do know 
that genetic factors are a major determinant of TSH 
and FT4 levels, next to individual and environmental 
factors such as age, gender, BMI, and iodine status (15). 
Future studies should therefore investigate if these fac-
tors can be used to predict the individual TSH and TH 
setpoint, which is a first step towards the personalized 
treatment of thyroid disease patients. This is important, 
as ~10% of hypothyroid patients on T4 treatment have 
persisting hypothyroid complaints (104, 105), which 
could be partially explained by the fact that their TSH 
and FT4 levels, despite being in the reference range, still 
deviate from their individual setpoint.
Moreover, knowing the individual TSH setpoint 
could be particularly useful in individuals with TSH 
levels close to (above/below) the upper limit of the 
reference range. This likely concerns a heterogeneous 
group, including individuals with normal thyroid func-
tion (ie, a setpoint at the extremes of the normal distri-
bution) as well as individuals with (mild, early stage) 
thyroid disease. This is expected to be important as 
observational studies showed that subclinical hypo-
thyroidism but also minor alterations in thyroid 
function are associated with adverse cardiovascular 
outcomes (2–4). Knowing the individual TSH setpoint 
could therefore further direct personalized treatment 
decisions. However, a better insight into the genetic 
determinants of thyroid function is still required in 
order to fully address this research question, as dis-
cussed below.
Knowledge Gaps and Further Research 
Directions
While recent GWAS have led to an impressive increase 
in the identification of variants associated with thyroid 
function, these variants so far only explain 33% and 
21% of the genetic variance in TSH and FT4 levels, re-
spectively (19). This is still a major limitation for all 
clinical applications discussed above and identifying 
this “missing heritability” (106) will be a key task for 
this field.
Further GWAS, WES, and WGS studies
The results of genetic association studies in complex 
traits and disorders, such as thyroid function and car-
diovascular disease, have demonstrated that a large 
part of their genetic susceptibility is defined by multiple 
common variants with modest individual effect sizes. 
Therefore some of the “missing heritability” may be ex-
plained by common polymorphisms that contribute to 
the genetic susceptibility with even smaller effect sizes 
than those already identified in previous GWAS. For 
this, larger GWAS are needed. Moreover, while most of 
GWAS performed so far included mainly Caucasians 
(19, 22-28), future studies should also investigate the 
genetic basis of thyroid function in other ethnic groups. 
This is important since interethnic variations in allele 
frequencies may result in substantial differences in effect 
sizes and overall contribution for the identified variants 
across populations. Although requiring large sample 
sizes, gene–gene and gene–environment interactions, 
such as with iodine status, should also be investigated 
in these future studies, as these are potentially signifi-
cant contributors to the genetic architecture of complex 
traits and disorders (107, 108).
While GWAS on thyroid function managed to identify 
multiple variants associated with TSH and FT4 levels, 
still little is known on the genetic factors determining 
FT3 levels, as they were not assessed in well-powered 
studies. Triiodothyronine (T3) is the active form of TH 
responsible for most of its metabolic effects (109). In 
2010, a GWAS performed by Panicker et al in a cohort 
of 2014 female twins from the British population failed 
to identify any variants associated with FT3 levels at 
the genome-wide significant level (25). Most recently, 
another small (N = 1731) GWAS in the Croatian popu-
lation identified the EPH receptor B2  (EPHB2) gene 
variant (rs67142165) as a new locus for FT3 levels 
(110). However, this finding requires confirmation in an 
independent study. Therefore, similar to TSH and FT4, 
well-powered GWAS meta-analyses are needed to effect-
ively investigate the genetic determinants of FT3 levels.
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Of note, there may be also rare variants conferring 
larger effects that can be identified in whole genome 
sequencing (WGS) or whole exome sequencing (WES) 
studies (106). The potential success of such studies is, 
for example, illustrated by a WGS study in 21 620 un-
related individuals of European ancestry, which showed 
that rare variants can be responsible for approximately 
54% and 51% of heritability for height and BMI, re-
spectively (111). While the first WGS study on thyroid 
function performed by Taylor et  al managed to iden-
tify only two novel loci associated with TSH and TH 
levels (B4GALT6 and SYN2) (34), further WES or WGS 
studies with larger sample size are expected to identify 
more rare variants that could explain a substantial pro-
portion of the “missing heritability” (112).
Epigenetic determinants of thyroid function and 
other omics in consortia
Epigenetic modifications such as DNA methyla-
tion, acetylation, phosphorylation, ubiquitination, 
and methylation of histones can regulate gene ex-
pression by alternations in DNA configuration. These 
nonpermanent changes are involved in cell prolifer-
ation and differentiation, but some of them can also be 
heritable or modified by environmental factors (113). 
Therefore, epigenetic modifications can be responsible 
for an important part of the “missing heritability” 
(114). While other fields in medicine have made sig-
nificant progress in the understanding of the role of 
methylation (115, 116), its role in the regulation of 
thyroid function is still poorly understood. Therefore, 
further studies, including epigenome-wide association 
studies (EWAS), are warranted.
Finally, population-based studies employing other 
omics, such as transcriptomics, proteomics, and 
metabolomics, are outside the scope of this review, but 
they may also lead to new insights in thyroid physi-
ology and pathophysiology, as recently discussed else-
where (117).
Functional studies
As mentioned before, an important part of the loci 
identified in GWAS on thyroid function has no known 
role yet in TH regulation. As illustrated by the AADAT 
and the SLC17A4 examples (19), further in vitro studies 
are a key step to discover new players involved in the 
regulation of thyroid function and investigate their po-
tential role in thyroid disease. Similarly, in vitro studies 
are also needed for the newly associated variants in 
known TH pathway genes, which will further increase 
our understanding of TH regulation.
Conclusions
In recent years, GWAS have identified many novel 
genetic variants, which determine individual TSH and 
FT4 levels. These findings have not only led to the 
discovery of new genes that play a role in regulation 
of thyroid function, but have also paved the way for 
various other applications. Mendelian Randomization 
studies are expected to improve our understanding of 
the relationships between thyroid (dys)function and 
various adverse health outcomes. Furthermore, with 
the identified genetic variants, we can start exploring 
ways to use these in future clinical practice, including 
thyroid disease risk prediction and personalization of 
its treatment. However, as their discriminative power 
is expected to still be too limited to be used in clinical 
practice yet, future studies in large-scale consortia are 
needed to decipher the unexplained genetic variance in 
thyroid function.
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